Diabetes from pancreas removal may be manageable side effect

Share this content:
Patients who undergo total pancreatectomy (TP) as a treatment for cancer or precancerous cysts in the pancreas may be able to achieve glycemic control similar to that seen in persons with type 1 diabetes who use insulin replacement, a small study indicates.  

TP is the best treatment for diffuse intraductal papillary mucinous neoplasm (IPMN), a potentially precancerous and potentially curable cystic condition that can be a precursor to pancreatic adenocarcinoma, noted Michael B. Wallace, MD, chair of the Division of Gastroenterology and Hepatology at the Mayo Clinic in Jacksonville, Florida, and colleagues in HPB Surgery. However, glycemic control following TP has been thought to be difficult to manage.

Wallace's team sought to compare glycemic control in persons undergoing TP for IPMN with glycemic control in persons with type 1 diabetes mellitus by retrospectively evaluating hemoglobin A1c (HbA1c) levels. Mean HbA1c at 6, 12, 18, and 24 months post-TP was similar between 14 persons who had had the surgery and 100 control patients with type 1 diabetes. (In the latter group, baseline was defined as 6 months prior to the first HbA1c measure.)

Specifically, mean HbA1c readings were as follows:

  • 6-month measures: 7.5% for TP group vs 7.7% for diabetes group
  • 12-month measures: 7.3% for TP group vs 8.0% for diabetes group
  • 18-month measures: 7.7% for TP group vs 7.6% for diabetes group
  • 24-month measures: 7.3% for TP group vs 7.8% for diabetes group.

Seven (50%) of the patients who underwent TP experienced a hypoglycemic event compared with 65 (65%) of the members of the diabetes group.

Despite the retrospective design of the study, small sample size, and lack of long-term follow-up, the investigators concluded that fear of post-TP diabetes should not be used to rule out TP when such surgery is a treatment option.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs